Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/14/2003WO2002026710A1 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis
03/14/2003CA2422613A1 5-phenylbenzylamine compound, process for preparing the same and synthetic intermediate thereof
03/13/2003WO2003021262A1 Screening method
03/13/2003WO2003020947A2 Mid 9002, a human sulfatase family member and uses therefor
03/13/2003WO2003020930A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS
03/13/2003WO2003020765A2 Vaccine therapies and prophylactic treatments of atherosclerotic diseases
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020749A2 Ncam binding compounds
03/13/2003WO2003020730A1 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents
03/13/2003WO2003020729A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS
03/13/2003WO2003020728A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
03/13/2003WO2003020724A1 Polycyclic guanine phosphodiesterase v inhibitors
03/13/2003WO2003020721A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/13/2003WO2003020719A1 1,3-benzothiazinone derivatives and use thereof
03/13/2003WO2003020710A1 Benzothiazepine derivatives
03/13/2003WO2003020703A1 Cyclic amine compound
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020694A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
03/13/2003WO2003020329A1 Hormone-coated stent for preventing stenosis or atherosclerosis
03/13/2003WO2003020325A2 Methods for sterilizing preparations containing albumin
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020315A1 Medicinal compositions containing angiotensin ii receptor antagonist
03/13/2003WO2003020312A1 Remedy for ischemic heart failure
03/13/2003WO2003020310A1 Preventives and/or remedies for diseases caused by endosteal microcirculatory disorders
03/13/2003WO2003020301A1 Chromogranin a and fragments thereof for the treatment of diseases involving increased vascular permeability
03/13/2003WO2003020282A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003WO2003020280A2 Compositions and use thereof in the treatment of cancer
03/13/2003WO2003020278A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
03/13/2003WO2003020269A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
03/13/2003WO2003020263A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020256A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003WO2003020255A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003WO2003020254A1 Pharmaceutical composition comprising (-)-secoisolariciresinol
03/13/2003WO2003020243A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin
03/13/2003WO2003020215A2 Methods of treating mycocardial event related coditions with thymosin beta 4
03/13/2003WO2003020202A2 Method for reducing hypertension and heart failure
03/13/2003WO2003020201A2 Pre-mixes of glp-1 and basal insulin
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2002099038A3 Adsls as modifiers of the p53 pathway and methods of use
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002078625A3 Therapeutic combinations for cardiovascular and inflammatory indications
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002076950A3 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002072033A3 Chronotherapeutic dosage forms containing glucocorticosteroid
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002058706A3 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
03/13/2003WO2002058696A3 The use of substituted azetidinone compounds for the treatment of sitosterolemia
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002050286A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002046412A3 Regulation of angiogenesis with zinc finger proteins
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036829A3 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002026984A3 Potassium channel interactors and uses therefor
03/13/2003WO2002023190A3 Methods and products related to low molecular weight heparin
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002022113A3 Retinoic acid receptor antagonists as promoters of angiogenesis
03/13/2003WO2002020056A3 Methods and compositions for producing a neurosalutary effect in a subject
03/13/2003WO2002016416A3 Diagnosis and treatment of cardiovascular conditions
03/13/2003WO2002015893A3 Treatment of wounds
03/13/2003WO2002014487A3 Adeno-associated virus-mediated delivery of angiogenic factors
03/13/2003WO2002014471A3 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
03/13/2003WO2002013797A3 Therapeutic combination of a cetp inhibitor and atorvastatin
03/13/2003WO2002010347A3 Directed differentiation of embryonic cells
03/13/2003WO2002008401A3 Elongase genes and uses thereof
03/13/2003WO2002008284A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002000690A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
03/13/2003WO2001096598A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
03/13/2003WO2001082911A3 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
03/13/2003US20030050466 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cancer or autoimmune diaseses
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050329 Synergistic combination comprising roflumilast and a PDE-3 inhibitor
03/13/2003US20030050328 Methods for treating hypertension, angina, and congestive heart failure using of optically pure (-) amlodipine
03/13/2003US20030050314 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050309 A gelatinase inhibitor for modulating the activity of a dopamine, serotonin, or norepinephrine receptor or transporter
03/13/2003US20030050304 Therapeutic compounds
03/13/2003US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050294 Controlled release formulation for preventing or treating risk factors for cardiovascular disease
03/13/2003US20030050289 Combination of drospirenone and an estrogen sulphamate for HRT
03/13/2003US20030050284 Administering to a subject before the onset of an ischemic episode at daily dosages of 1-2 g of free cdp-choline
1 ... 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 ... 1595